Clinical Trial Update: Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting safety, tolerability, and pharmacokinetics results of intravitreal pegaptanib sodium at 1 mg/eye and 3 mg/eye in exudative Age-R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Eyetech Pharmaceuticals | Conditions: Age-Related Macular Degeneration | Phase 2, Phase 3 | Status: COMPLETED